In adults at high CV risk and without previous MI or stroke, evolocumab reduced major adverse CV event composites at a median 4.6 y.
Where this comes from
- Record sourced from PubMed, PMID 41771125.
- Also identified by DOI 10.7326/ANNALS-25-05604-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text].
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Anticholesteremic Agents
- Cardiovascular Diseases
- Antibodies, Monoclonal